Update on proposal to fund two new medicines for type 2 diabetes
PHARMAC would like to thank everyone who provided feedback on a proposal to fund two new medicines, empagliflozin (with and without metformin) and dulaglutide, for type 2 diabetes.
This proposal was the subject of a consultation letter dated 9 September 2020, with a closing date for feedback of 2 October 2020.
Consultation is a very important step in our process. It’s how we check that what we are proposing can be implemented by the health sector and that the people who will get the most benefit from the medicines will be able to access them.
After having reviewed the consultation feedback, we have determined that we require additional time to consider the matters raised before a decision can be made on the proposal. This means that a decision will not be made in time to implement the proposal from the earliest possible listing date of 1 December 2020 that was noted in the consultation. At this stage, we do not have a firm timeframe for when a decision will be made.
If you have any questions about this update, please contact us by email at email@example.com